First Manhattan’s Coherus Oncology CHRS Stock Holding History

First Manhattan’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-3,500	Closed	-$13.1K	–	1458
2023 Q3	$13.1K	Hold	3,500	–	–	﹤0.01%	1084
2023 Q2	$14.9K	Hold	3,500	–	–	﹤0.01%	1078
2023 Q1	$23.9K	Hold	3,500	–	–	﹤0.01%	1053
2022 Q4	$27.7K	Hold	3,500	–	–	﹤0.01%	1040
2022 Q3	$33K	Hold	3,500	–	–	﹤0.01%	997
2022 Q2	$25K	Hold	3,500	–	–	﹤0.01%	1075
2022 Q1	$45K	Hold	3,500	–	–	﹤0.01%	1022
2021 Q4	$55K	Hold	3,500	–	–	﹤0.01%	975
2021 Q3	$56K	Hold	3,500	–	–	﹤0.01%	965
2021 Q2	$48K	Hold	3,500	–	–	﹤0.01%	991
2021 Q1	$51K	Hold	3,500	–	–	﹤0.01%	957
2020 Q4	$60K	Hold	3,500	–	–	﹤0.01%	873
2020 Q3	$64K	Hold	3,500	–	–	﹤0.01%	848
2020 Q2	$62K	Hold	3,500	–	–	﹤0.01%	838
2020 Q1	$56K	Hold	3,500	–	–	﹤0.01%	826
2019 Q4	$63K	Hold	3,500	–	–	﹤0.01%	868
2019 Q3	$70K	Buy	+3,500	New	+$69.9K	﹤0.01%	849
2015 Q4	–	Sell	-5,000	Closed	-$100K	–	1420
2015 Q3	$100K	Buy	+5,000	New	+$152K	﹤0.01%	806

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Manhattan's CHRS Position: Q4 2023 in Review

First Manhattan sold out of Coherus Oncology (CHRS) in Q4 2023, closing a stake of 3,500 shares — an estimated $13.1K sold.

First Manhattan first reported a position in CHRS in Q3 2015 and held it in 18 quarters. The position peaked at $100K in Q3 2015. 156 funds tracked by Wall St. Rank hold CHRS as of Q4 2023.

First Manhattan reported no remaining Coherus Oncology position as of Q4 2023 after selling out during the quarter.
First Manhattan sold 3,500 Coherus Oncology shares in Q4 2023, an estimated $13.1K.
First Manhattan first reported a position in Coherus Oncology in Q3 2015 and held it in 18 quarters.
First Manhattan's Coherus Oncology position peaked at $100K in Q3 2015.
156 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2023.

Based on First Manhattan's 13F filing for Q4 2023, filed 13 Feb 2024.